Significantly more DUPIXENT patients achieved a meaningful response in both itch and nodule clearance, meeting both a ≥4-point improvement in WI-NRS and an
IGA PN-S score of 0 or 1 at Week 241,2
PRIME
Proportion (%) of patients achieving ≥4‑point improvement in WI‑NRS + IGA PN‑S 0 or 1
- A nominal difference was observed at Week 8 (12% with DUPIXENT vs 0% with placebo) and at Week 12 (20% with DUPIXENT vs 5% with placebo)3
PRIME2
- At Week 8 and Week 12, 8% and 17% of patients treated with DUPIXENT vs 5% and 9% with placebo, respectively, had both improvement in itch and nodule clearance. A significantly greater proportion of DUPIXENT patients achieved both improvement in itch and nodule clearance at Week 24 (32% with DUPIXENT vs 9% with placebo; P<0.001)1-3
Definitive conclusions cannot be made for results earlier than at 24 weeks in PRIME and PRIME2.
Data
were not multiplicity controlled.
IGA PN-S, Investigator’s Global Assessment PN-Stage; Q2W, once every 2 weeks; WI-NRS, Worst Itch numerical rating scale.
Dosage and administration
Thinking about prescribing DUPIXENT? Find the information you need to get started.